BioCentury
ARTICLE | Translation in Brief

Presenting p53

How a new antibody hits p53-mutant cancers

April 13, 2017 7:30 PM UTC

A team from University of Oxford has described a new way to hit most mutant forms of the notoriously intractable cancer target p53 using a single therapeutic agent, and believes it could suppress growth of almost any p53-expressing tumor.

In a Cancer Research paper published last month, a group led by Oxford senior research fellow Demin Li designed an antibody that can bind a fragment of wild-type p53 when presented on the cell surface by major histocompatibility complex class I A 2 (HLA-A2). ...

BCIQ Company Profiles

University of Oxford

BCIQ Target Profiles

Tumor protein p53 (TP53) (p53)